Form 8-K - Current report:
SEC Accession No. 0001193125-25-141085
Filing Date
2025-06-16
Accepted
2025-06-16 06:44:22
Documents
18
Period of Report
2025-06-13
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d150245d8k.htm   iXBRL 8-K 39162
2 EX-1.1 d150245dex11.htm EX-1.1 271804
3 EX-4.1 d150245dex41.htm EX-4.1 71798
4 EX-5.1 d150245dex51.htm EX-5.1 11887
5 EX-99.1 d150245dex991.htm EX-99.1 8267
9 GRAPHIC g150245g0614023757932.jpg GRAPHIC 3225
10 GRAPHIC g150245g0614023758328.jpg GRAPHIC 1396
  Complete submission text file 0001193125-25-141085.txt   629836

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA elvn-20250613.xsd EX-101.SCH 2886
7 XBRL TAXONOMY EXTENSION LABEL LINKBASE elvn-20250613_lab.xml EX-101.LAB 17978
8 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE elvn-20250613_pre.xml EX-101.PRE 11282
20 EXTRACTED XBRL INSTANCE DOCUMENT d150245d8k_htm.xml XML 3629
Mailing Address 6200 LOOKOUT ROAD BOULDER CO 80301
Business Address 6200 LOOKOUT ROAD BOULDER CO 80301 720-647-8519
Enliven Therapeutics, Inc. (Filer) CIK: 0001672619 (see all company filings)

EIN.: 811523849 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39247 | Film No.: 251048502
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)